Sonic Hedgehog Pathway as the Prognostic Marker in Patients with Extensive Stage Small Cell Lung Cancer

被引:22
|
作者
Lim, Seungtaek [1 ,2 ]
Lim, Sun Min [3 ]
Kim, Min-Ju [4 ]
Park, Shin Young [5 ]
Kim, Joo-Hang [3 ]
机构
[1] Yonsei Univ, Wonju Coll Med, Wonju Severance Christian Hosp, Dept Hernatooncol, Wonju, South Korea
[2] Konyang Univ, Myunggok Med Res Inst, Daejeon, South Korea
[3] CHA Univ, CHA Bundang Med Ctr, Dept Internal Med, Div Med Oncol, 59 Yatap Ro, Seongnam 13496, South Korea
[4] Seegen Med Fdn, Seoul, South Korea
[5] Daejeon Son Hosp, Dept Pathol, Daejeon, South Korea
关键词
Small cell lung cancer; prognostic factors; hedgehog proteins; drug therapy; HUMAN HOMOLOG; CHEMOTHERAPY; COMBINATION; INHIBITION; CISPLATIN; GEFITINIB; GROWTH; TRIAL; PLUS;
D O I
10.3349/ymj.2019.60.10.898
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Sonic hedgehog (Shh) signaling pathway is known to play a crucial role in carcinogenesis in various malignancies, including lung cancer regarding tumorigenesis, angiogenesis, and cellular differentiation. The aim of this study was to investigate the value of components of Shh pathway as a prognostic marker in extensive stage small cell lung cancer (ES-SCLC) patients. Materials and Methods: We retrospectively analyzed data of 36 patients who were diagnosed with ES-SCLC between 2008 and 2012 at a single center. We performed immuo-histochemistry for glioma-associated oncogene homolog zinc finger protein 1 (Gli1), patched, Shh, and Ptch-mediated repression of smoothened (Smo) proteins using formalin-fixed, paraffin-embedded tissue derived from primary tumors. We then conducted survival analysis to evaluate the prognostic impact of these markers. Results: All 36 patients received platinum-based doublet chemotherapy. The median progression free survival and median overall survival were 6.9 months [95% confidence interval (CI), 6.5-7.3] and 11.7 months (95% CI, 9.1-14.3), respectively. The overall response rate was 84%. Of the 36 tissue specimens examined, over-expression of Gli1, Patched, Shh, and Smo was found in 12 (33.3%), five (13.9%), five (13.9%), and six (16.7%) cases, respectively. We found that high expression of Shh was associated with worse progression free survival (6.3 vs. 7.6 months, p=0.005) and overall survival (9.2 vs. 12.0 months, p=0.039) by both univariate and multivariate analyses, whereas other markers were not related to patient prognosis. Conclusion: A high proportion of small cell lung cancer tumors express proteins related to Shh pathway, and over-expression of Shh is correlated with poor prognosis.
引用
收藏
页码:898 / 904
页数:7
相关论文
共 50 条
  • [21] Outcomes and Prognostic Factors of Extensive Stage Small Cell Lung Cancer: A Retrospective Study
    Veena, P. S.
    Sajeed, A.
    Geethi, M. H.
    Krishna, K. M. Jagathnath
    Sivananadan, C. D.
    Sankar, S. Arun
    Roshni, S.
    Lijeesh, A. L.
    SOUTH ASIAN JOURNAL OF CANCER, 2023,
  • [22] The prognostic values of prognostic nutritional index in extensive-stage small-cell lung cancer
    Bahceci, Aykut
    Sedef, Ayse Kotek
    Isik, Deniz
    ANTI-CANCER DRUGS, 2022, 33 (01) : E534 - E540
  • [23] Extensive stage small cell lung cancer.
    Niell H.B.
    Current Treatment Options in Oncology, 2001, 2 (1) : 71 - 76
  • [24] Immunotherapy for extensive stage small cell lung cancer
    Pacheco, Jose M.
    JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 6212 - 6224
  • [25] Radiotherapy for Extensive Stage Small Cell Lung Cancer
    Slotman, B. J.
    CONTROVERSIES IN TREATMENT OF LUNG CANCER, 2010, 42 : 187 - 192
  • [26] Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer
    Takehiro Miyagi
    Daiki Tsuji
    Yohei Kawasakai
    Hiroshi Ishikawa
    Rei Tanaka
    Masahiko Nakao
    Shigeru Nakagaki
    Toshinobu Hayashi
    Hideaki Ayuhara
    Tomohiko Harada
    Shinya Tamaki
    Akimitsu Maeda
    Yasukata Ohashi
    Yuichiro Arakawa
    Yukiyoshi Fujita
    Keisuke Yamamoto
    Yasunori Miyamoto
    Takuya Yano
    Kunihiko Itoh
    European Journal of Clinical Pharmacology, 2023, 79 : 407 - 414
  • [27] Development of a prognostic model for patients with extensive-stage small cell lung cancer undergoing immunotherapy and chemotherapy
    Gao, Yunbin
    Zhang, Lixia
    Yan, Meng
    Sun, Zongwen
    Zhao, Haibo
    Zhao, Lujun
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [28] Prognostic Factors for Survival of Patients with Extensive Stage Small Cell Lung Cancer - a Retrospective Single Institution Analysis
    Wu, Chao
    Li, Fang
    Jiao, Shun-Chang
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (10) : 4959 - 4962
  • [29] Prognostic value of Ki-67 expression in patients with extensive-stage small cell lung cancer
    Pei, Renguang
    Zhang, Liqin
    Xie, Chao
    Lu, Zhiwei
    Wang, Guoxiang
    Yang, Zhimin
    FUTURE ONCOLOGY, 2017, 13 (14) : 1247 - 1252
  • [30] Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer
    Miyagi, Takehiro
    Tsuji, Daiki
    Kawasakai, Yohei
    Ishikawa, Hiroshi
    Tanaka, Rei
    Nakao, Masahiko
    Nakagaki, Shigeru
    Hayashi, Toshinobu
    Ayuhara, Hideaki
    Harada, Tomohiko
    Tamaki, Shinya
    Maeda, Akimitsu
    Ohashi, Yasukata
    Arakawa, Yuichiro
    Fujita, Yukiyoshi
    Yamamoto, Keisuke
    Miyamoto, Yasunori
    Yano, Takuya
    Itoh, Kunihiko
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (03) : 407 - 414